Product information and disease descriptionProduct descriptionProduct information
Access and distribution
8 evidence topics · 5 sources
Current access through clinical trials only
Schedule I status: product rescheduling required before commercial distribution
DEA registration of clinical trial sites and importation for the trials
Manufacturing quotas for the active ingredient after approval
Planned delivery through certified third-party treatment sites and a possible REMS
Monitoring requirement in the pivotal trials and the end-of-session checklist as a basis for a potential REMS
Planned sites of care: interventional psychiatry clinics
Manufacturing and supply: contract manufacturers and a single supplier of lysergide tartrate
Distribution channel and specialty pharmacy arrangements
No evidence found.